In Yu Tan
In Yu Tan has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
Albert P. Aldenkamp
Department of Behavioral Sciences, Kempenhaeghe Epilepsy Center, PO Box 61, 5590AB Heeze, the Netherlands; Department of Neurology, Maastricht University Medical Center, PO Box 616, 6200MD, Maastricht, the Netherlands; Department of Neurology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium; Department of Electrical Engineering, University of Technology, PO Box 513, Eindhoven, the Netherlands
8 shared publications- Marian Majoie
School of Health Professions Education, Maastricht University, The Netherlands
8 shared publications - Jans S. van Ool
Department of Residential Care Kempenhaeghe Epilepsy Center Heeze The Netherlands
6 shared publications - Francesca M. Snoeijen-Schouwenaars
Department of Residential Care, Kempenhaeghe Epilepsy Center, Heeze, The Netherlands
5 shared publications - Jessica Johanna Leonarda Berkvens
Department of Residential Care, Epilepsy Center Kempenhaeghe, Heeze, The Netherlands
5 shared publications A.P. Aldenkamp
Department of Residential Care, Epilepsy Center Kempenhaeghe, Heeze, The Netherlands; Department of Neurology, Academic Center for Epileptology Kempenhaeghe/Maastricht University Medical Center, The Netherlands
4 shared publications
Latest Publications
- 17 October 2022
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 103, 32-38
Assessment of Trabecular Bone Score: a 7-year follow-up study in institutionalized adults with refractory epilepsy and intellectual disability
- 17 October 2022
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 103, 32-38
Assessment of Trabecular Bone Score: a 7-year follow-up study in institutionalized adults with refractory epilepsy and intellectual disability
- 2 September 2021
- Published by Wiley in Journal of Intellectual Disability Research
- Vol. 65 (11) , 962-970
Bone mineral density and fractures in institutionalised children with epilepsy and intellectual disability
Background: Long‐term use of antiseizure drugs is associated with a low bone mineral density (BMD) and an increased fracture risk. The literature regarding institutionalised children on chronic antiseizure drugs is limited. Therefore, the aim of this cross‐sectional study is to evaluate the prevalence of low BMD and the history of fractures in institutionalised children with epilepsy and intellectual disability (ID).Methods: A dual‐energy X‐ray absorptiometry of lumbar spine (L1–L4) and hip was performed in 24 children, residing in a long‐stay care facility in the Netherlands. Additionally, serum concentrations of albumin, calcium and 25‐hydroxyvitamin D were determined. Data on fractures were retrospectively extracted from the medical files.Results: Ages of the children (14 male and 10 female) ranged from 5 to 17 years with a mean age of 13.0 (±3.2). The criteria of the International Society for Clinical Densitometry (ISCD) were used for classification of bone mineral disorders. Eight (33.3%) children had a normal BMD (Z‐score > − 2.0). Of the 16 children with a low BMD (Z‐score ≤ − 2.0), three were diagnosed as osteoporotic, based on their fracture history. Ten children (41.7%) were reported to have at least one fracture in their medical history. Serum concentrations of albumin‐corrected calcium (2.28–2.50 mmol/L) and (supplemented) vitamin D (16–137 nmol/L) were within the normal range.Conclusions: This study demonstrated that 67% of institutionalised children with epilepsy and ID had low BMD and 42% had a history of at least one fracture, despite supplementation of calcium and vitamin D in accordance with the Dutch guidelines.
- 2 September 2021
- Published by Wiley in Journal of Intellectual Disability Research
- Vol. 65 (11) , 962-970
Bone mineral density and fractures in institutionalised children with epilepsy and intellectual disability
Background: Long‐term use of antiseizure drugs is associated with a low bone mineral density (BMD) and an increased fracture risk. The literature regarding institutionalised children on chronic antiseizure drugs is limited. Therefore, the aim of this cross‐sectional study is to evaluate the prevalence of low BMD and the history of fractures in institutionalised children with epilepsy and intellectual disability (ID).Methods: A dual‐energy X‐ray absorptiometry of lumbar spine (L1–L4) and hip was performed in 24 children, residing in a long‐stay care facility in the Netherlands. Additionally, serum concentrations of albumin, calcium and 25‐hydroxyvitamin D were determined. Data on fractures were retrospectively extracted from the medical files.Results: Ages of the children (14 male and 10 female) ranged from 5 to 17 years with a mean age of 13.0 (±3.2). The criteria of the International Society for Clinical Densitometry (ISCD) were used for classification of bone mineral disorders. Eight (33.3%) children had a normal BMD (Z‐score > − 2.0). Of the 16 children with a low BMD (Z‐score ≤ − 2.0), three were diagnosed as osteoporotic, based on their fracture history. Ten children (41.7%) were reported to have at least one fracture in their medical history. Serum concentrations of albumin‐corrected calcium (2.28–2.50 mmol/L) and (supplemented) vitamin D (16–137 nmol/L) were within the normal range.Conclusions: This study demonstrated that 67% of institutionalised children with epilepsy and ID had low BMD and 42% had a history of at least one fracture, despite supplementation of calcium and vitamin D in accordance with the Dutch guidelines.
- 1 November 2020
- Published by Elsevier in Epilepsy Research
- Vol. 167, 106461
Prevalence and incidence of vertebral fractures: a 7-year follow-up study in institutionalized adults with refractory epilepsy and intellectual disability
- 1 November 2020
- Published by Elsevier in Epilepsy Research
- Vol. 167, 106461
Prevalence and incidence of vertebral fractures: a 7-year follow-up study in institutionalized adults with refractory epilepsy and intellectual disability
- Open Access
- 8 May 2020
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 142 (3) , 255-259
European perspective of perampanel response in people with Intellectual Disability
Background Epilepsy prevalence is over 20% for those with ID. It is difficult to diagnose and treat and more likely to be treatment resistant. The evidence informing prescribing is sparse, particularly for new drugs such as Perampanel (PMP). Aims of the Study This study seeks to strengthen the research evidence regarding PMP for people with ID by pooling information from two isolated and separately conducted studies: the UK based Epilepsy Database Register (Ep‐ID) and the data from the Kempenhaeghe clinic in the Netherlands. Methods A single dataset of comparable data was created and analysed under agreement and supervision of a UK statistician. Results Seizure reduction within twelve months was evident in 62% of Dutch and 47% of UK patients. Retention rates were higher for those in the UK (P=0.01) and for patients with moderate to profound ID, whilst side effects were more prominent in the Dutch cohort. Conclusions Comparable rates of seizure reduction are in line with estimates for non‐ID patients, adding to the evidence suggesting that PMP has a similar impact on those with ID. Taking a European perspective and sharing data across centres can help strengthen the evidence for prescribing antiepileptic drugs in the ID population.
- 8 May 2020
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 142 (3) , 255-259
Open AccessEuropean perspective of perampanel response in people with Intellectual Disability
Background Epilepsy prevalence is over 20% for those with ID. It is difficult to diagnose and treat and more likely to be treatment resistant. The evidence informing prescribing is sparse, particularly for new drugs such as Perampanel (PMP). Aims of the Study This study seeks to strengthen the research evidence regarding PMP for people with ID by pooling information from two isolated and separately conducted studies: the UK based Epilepsy Database Register (Ep‐ID) and the data from the Kempenhaeghe clinic in the Netherlands. Methods A single dataset of comparable data was created and analysed under agreement and supervision of a UK statistician. Results Seizure reduction within twelve months was evident in 62% of Dutch and 47% of UK patients. Retention rates were higher for those in the UK (P=0.01) and for patients with moderate to profound ID, whilst side effects were more prominent in the Dutch cohort. Conclusions Comparable rates of seizure reduction are in line with estimates for non‐ID patients, adding to the evidence suggesting that PMP has a similar impact on those with ID. Taking a European perspective and sharing data across centres can help strengthen the evidence for prescribing antiepileptic drugs in the ID population.
- 10 March 2020
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 121 (3) , 677-684
Efficacy and tolerability of brivaracetam in patients with intellectual disability and epilepsy
Patients with intellectual disability (ID) are often excluded from clinical trials, and little is known about the best approach to treat their epilepsy. Brivaracetam (BRV) is a new antiepileptic drug (AED) for adjunctive treatment in patients with focal-onset seizures with or without secondary generalization. We analyzed the efficacy and tolerability of BRV in patients with ID and epilepsy who either had or had not previously received treatment with levetiracetam (LEV). Data on efficacy and tolerability were retrospectively collected. After the initial start of BRV in our tertiary epilepsy center, we analyzed medical records at 0, 3, 6 and 12 months of follow-up. 116 patients were included (mean age = 34.9 years, 44% female). All had complete data of 3-month follow-up, 76 of 6-month follow-up, and 39 patients of 1-year follow-up. Median starting dose of BRV was 50.0 mg/day and the mean number of concomitant AEDs was 2.6. Seizure reduction and no side effects were reported in more than half of all patients. The most reported side effects were somnolence, dizziness and aggression. Retention rates for BRV were 84.4%, 75.5% and 58.1% after 3, 6 and 12 months, respectively. Seizure reduction and side effects did not differ significantly between the groups with or without previous LEV treatment. We demonstrate that BRV is effective and well tolerated in patients with epilepsy and ID, even in those where previous LEV treatment failed.
- 10 March 2020
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 121 (3) , 677-684
Efficacy and tolerability of brivaracetam in patients with intellectual disability and epilepsy
Patients with intellectual disability (ID) are often excluded from clinical trials, and little is known about the best approach to treat their epilepsy. Brivaracetam (BRV) is a new antiepileptic drug (AED) for adjunctive treatment in patients with focal-onset seizures with or without secondary generalization. We analyzed the efficacy and tolerability of BRV in patients with ID and epilepsy who either had or had not previously received treatment with levetiracetam (LEV). Data on efficacy and tolerability were retrospectively collected. After the initial start of BRV in our tertiary epilepsy center, we analyzed medical records at 0, 3, 6 and 12 months of follow-up. 116 patients were included (mean age = 34.9 years, 44% female). All had complete data of 3-month follow-up, 76 of 6-month follow-up, and 39 patients of 1-year follow-up. Median starting dose of BRV was 50.0 mg/day and the mean number of concomitant AEDs was 2.6. Seizure reduction and no side effects were reported in more than half of all patients. The most reported side effects were somnolence, dizziness and aggression. Retention rates for BRV were 84.4%, 75.5% and 58.1% after 3, 6 and 12 months, respectively. Seizure reduction and side effects did not differ significantly between the groups with or without previous LEV treatment. We demonstrate that BRV is effective and well tolerated in patients with epilepsy and ID, even in those where previous LEV treatment failed.
Diagnostic exome sequencing in 100 consecutive patients with both epilepsy and intellectual disability
Summary: Objective: Epilepsy is highly prevalent among patients with intellectual disability (ID), and seizure control is often difficult. Identification of the underlying etiology in this patient group is important for daily clinical care. We assessed the diagnostic yield of whole exome sequencing (WES). In addition, we evaluated which clinical characteristics influence the likelihood of identifying a genetic cause and we assessed the potential impact of the genetic diagnosis on (antiepileptic) treatment strategy.Methods: One hundred patients with both unexplained epilepsy and (borderline) ID (intelligence quotient ≤ 85) were included. All patients were evaluated by a clinical geneticist, a (pediatric) neurologist, and/or a specialist ID physician. WES analysis was performed in two steps. In step 1, analysis was restricted to the latest versions of ID and/or epilepsy gene panels. In step 2, exome analysis was extended to all genes (so‐called full exome analysis). The results were classified according to the American College of Medical Genetics and Genomics guidelines.Results: In 58 patients, the diagnostic WES analysis reported one or more variant(s). In 25 of the 100 patients, these were classified as (likely) pathogenic, in 24 patients as variants of uncertain significance, and in the remaining patients the variant was most likely not related to the phenotype. In 10 of 25 patients (40%) with a (likely) pathogenic variant, the genetic diagnosis might have an impact on the treatment strategy in the future.Significance: This study illustrates the clinical diagnostic relevance of WES for patients with both epilepsy and ID. It also demonstrates that implementing WES diagnostics might have impact on the (antiepileptic) treatment strategy in this population. Confirmation of variants of uncertain significance in (candidate) genes may further increase the yield.
Diagnostic exome sequencing in 100 consecutive patients with both epilepsy and intellectual disability
Summary: Objective: Epilepsy is highly prevalent among patients with intellectual disability (ID), and seizure control is often difficult. Identification of the underlying etiology in this patient group is important for daily clinical care. We assessed the diagnostic yield of whole exome sequencing (WES). In addition, we evaluated which clinical characteristics influence the likelihood of identifying a genetic cause and we assessed the potential impact of the genetic diagnosis on (antiepileptic) treatment strategy.Methods: One hundred patients with both unexplained epilepsy and (borderline) ID (intelligence quotient ≤ 85) were included. All patients were evaluated by a clinical geneticist, a (pediatric) neurologist, and/or a specialist ID physician. WES analysis was performed in two steps. In step 1, analysis was restricted to the latest versions of ID and/or epilepsy gene panels. In step 2, exome analysis was extended to all genes (so‐called full exome analysis). The results were classified according to the American College of Medical Genetics and Genomics guidelines.Results: In 58 patients, the diagnostic WES analysis reported one or more variant(s). In 25 of the 100 patients, these were classified as (likely) pathogenic, in 24 patients as variants of uncertain significance, and in the remaining patients the variant was most likely not related to the phenotype. In 10 of 25 patients (40%) with a (likely) pathogenic variant, the genetic diagnosis might have an impact on the treatment strategy in the future.Significance: This study illustrates the clinical diagnostic relevance of WES for patients with both epilepsy and ID. It also demonstrates that implementing WES diagnostics might have impact on the (antiepileptic) treatment strategy in this population. Confirmation of variants of uncertain significance in (candidate) genes may further increase the yield.
- Open Access
- 14 October 2018
- Published by Wiley in Journal of Intellectual Disability Research
- Vol. 63 (1) , 40-48
Classification of intellectual disability according to domains of adaptive functioning and between‐domains discrepancy in adults with epilepsy
Background: In the Diagnostic and Statistical Manual of Mental Disorders–Fifth edition (DSM‐5), the diagnostic criteria of intellectual disability (ID) include three domains of adaptive deficits: the conceptual, social and practical. Substantial intra‐individual differences between domains can be considered an ID domain discrepancy.Method: We explored the associations between ID domains, discrepancies and epilepsy in 189 adults (mean age = 47.9; SD = 15.6). Each DSM‐5 ID domain was assessed separately, using subscales of the Vineland II for the social and practical domains, and psychological instruments, including intelligence tests, for the conceptual domain. A set of standardised criteria is proposed to identify an ID domain discrepancy.Results: An ID domain discrepancy seemed to be present in about one‐third of subjects and was particularly present in subjects with moderate ID (53.4%). Impairment in the social domain was most often the reason for the discrepancy. The presence of a discrepancy was significantly related to a focal (localised) epilepsy type (OR = 2.3, P = .028) and a mixed seizure type (OR = 1.4, P = .009). Epilepsy characteristics that are indicative of a more severe and refractory epilepsy, including various seizure types, a high seizure frequency, a combined epilepsy type (both focal and generalised epilepsy) and an early age at onset, were significantly related to more severe impairments in conceptual, social and practical adaptive behaviour (all P values <.01).Conclusions: With a substantial proportion of the subjects who had both ID and epilepsy with an ID discrepancy, professionals should be aware of this and take all domains of ID into account when studying or working with this vulnerable population.
- 14 October 2018
- Published by Wiley in Journal of Intellectual Disability Research
- Vol. 63 (1) , 40-48
Open AccessClassification of intellectual disability according to domains of adaptive functioning and between‐domains discrepancy in adults with epilepsy
Background: In the Diagnostic and Statistical Manual of Mental Disorders–Fifth edition (DSM‐5), the diagnostic criteria of intellectual disability (ID) include three domains of adaptive deficits: the conceptual, social and practical. Substantial intra‐individual differences between domains can be considered an ID domain discrepancy.Method: We explored the associations between ID domains, discrepancies and epilepsy in 189 adults (mean age = 47.9; SD = 15.6). Each DSM‐5 ID domain was assessed separately, using subscales of the Vineland II for the social and practical domains, and psychological instruments, including intelligence tests, for the conceptual domain. A set of standardised criteria is proposed to identify an ID domain discrepancy.Results: An ID domain discrepancy seemed to be present in about one‐third of subjects and was particularly present in subjects with moderate ID (53.4%). Impairment in the social domain was most often the reason for the discrepancy. The presence of a discrepancy was significantly related to a focal (localised) epilepsy type (OR = 2.3, P = .028) and a mixed seizure type (OR = 1.4, P = .009). Epilepsy characteristics that are indicative of a more severe and refractory epilepsy, including various seizure types, a high seizure frequency, a combined epilepsy type (both focal and generalised epilepsy) and an early age at onset, were significantly related to more severe impairments in conceptual, social and practical adaptive behaviour (all P values <.01).Conclusions: With a substantial proportion of the subjects who had both ID and epilepsy with an ID discrepancy, professionals should be aware of this and take all domains of ID into account when studying or working with this vulnerable population.
- 1 September 2018
- Published by Elsevier in Epilepsy & Behavior
- Vol. 86, 72-78
Challenging behavior in adults with epilepsy and intellectual disability: An analysis of epilepsy characteristics
- 1 September 2018
- Published by Elsevier in Epilepsy & Behavior
- Vol. 86, 72-78
Challenging behavior in adults with epilepsy and intellectual disability: An analysis of epilepsy characteristics
- 1 July 2018
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 59, 67-71
Psychogenic nonepileptic seizures in adults with epilepsy and intellectual disability: A neglected area
- 1 July 2018
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 59, 67-71
Psychogenic nonepileptic seizures in adults with epilepsy and intellectual disability: A neglected area